Official EU label nameGlossary entry 25271

SARCOSINE

This record confirms an official common ingredient name for EU cosmetic product labelling. It does not by itself confirm that the substance is permitted, unrestricted or safe.

Global evidence snapshot

The resolved identity has matching regulatory evidence in 0 of 13 indexed market datasets: 0 country records and 0 EU Annex records. Every result and evidence gap is listed below.

0 markets with evidence
Markets checked
13
Markets with evidence
0
Evidence gaps
13
Resolved identifiers
2

A missing local match is not permission, approval or proof of safety. It means no strong identity match was resolved in that indexed dataset.

Resolved substance identity

CAS:107-97-1
EC:203-538-6
Ingredient index records:
SARCOSINE
Cosmetic functions: SKIN CONDITIONING

Glycine, N-methyl-

1 matched or reported name
SARCOSINE

Regulatory evidence in all 13 markets

Open each matched record for its scope, concentration, conditions, warnings and official source version.

Swipe or scroll horizontally to see dataset coverage and next actions.

MarketResultRecordsDatasetMeaning / next action
European Union
EU
No local match0
Complete annex dataset
Regulation (EC) 1223/2009 consolidated to 1 May 2026
No annex match only means that these five annexes did not return a match; CosIng identity data and other EU obligations still need review.
Great Britain
GB
No local match0
Complete consolidated annex dataset
GB retained Regulation 1223/2009 schedules, effective 15 August 2026
No annex match is not approval and does not cover Northern Ireland, which follows the applicable EU framework.
Canada
CA
No local match0
Complete Hotlist snapshot
Health Canada Cosmetic Ingredient Hotlist, 13 August 2025
The Hotlist is an administrative compliance tool, not an exhaustive safety approval list.
New Zealand
NZ
No local match0
Complete schedules dataset
Cosmetic Products Group Standard schedules effective 1 January 2026
The searchable spreadsheet is an aid; the legal Group Standard and incorporated notices remain authoritative.
ASEAN
ASEAN
No local match0
Complete regional annex dataset
ASEAN Cosmetic Directive annexes 2026-1, 22 June 2026
Regional annex coverage does not replace member-state implementation dates, notifications or national deviations.
China
CN
No local match0
Complete prohibited catalogues plus official-source workflow
NMPA 2021 banned catalogues plus dynamic IECIC List I/List II system current since 2025
IECIC listing is not blanket approval; absence may require the new cosmetic ingredient route, and restrictions are checked separately.
Japan
JP
No local match0
Complete Standards appendices dataset
MHLW Standards for Cosmetics official English source and Japanese amendments checked for the imported snapshot
The Japanese text and subsequent notices are canonical; no local match is not a product-compliance conclusion.
South Korea
KR
No local match0
Complete current appendix dataset
MFDS Notice 2026-19, effective 18 March 2026
Korean source wording is canonical and other positive lists/notices may still apply to the formulation.
United States
US
No local match0
Complete enumerated federal ingredient rules
eCFR Title 21 issue date 27 August 2026
FDA has no general approved-cosmetic-ingredient catalogue; absence from these sections is not approval or proof of safety.
Australia
AU
No local match0
Complete cosmetic-relevant Poisons Standard subset plus official workflow
Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026
An AICIS Inventory match is not cosmetic approval; no Inventory match can indicate a new, exempted, reported or confidential introduction.
Brazil
BR
No local match0
Complete prohibited dataset plus current restricted-list workflow
ANVISA RDC 1.029/2026 and RDC 1.030/2026, published 15 June 2026
RDC 1.030/2026 amends rather than replaces the prohibited baseline, and the second restricted-list revision was still under consultation in July 2026.
India
IN
No local match0
Complete current Part 2 dataset plus official workflow for Parts 1, 3 and 4
Cosmetics Rules 2020 plus current BIS IS 4707 parts (1:2020, 2:2025, 3:2025, 4:2022)
The standards are separate controlled publications; absence from a locally indexed excerpt is not permission.
Saudi Arabia
SA
No local match0
Complete official list index
SFDA live prohibited/restricted lists, snapshot 30 August 2026
No list match is not permission; Gulf/SFDA product, claim, notification and technical requirements still apply.
No market rows match this filter.

Chemical identity and properties

PubChem 2D chemical structure for CAS 107-97-1
CAS 107-97-1PubChem CID 1088

Sarcosine

IUPAC name
2-(methylamino)acetic acid
Molecular formula
C3H7NO2
Molecular weight
89.09 g/mol
Exact mass
89.047678466 Da
XLogP3
-2.8
Topological polar surface area
49.3 Ų
Hydrogen-bond donors
2
Hydrogen-bond acceptors
3
Covalent units
1
Defined stereocentres
0

Also known as

N-methylglycineSarcosinic acidMethylglycineGlycine, N-methyl-N-Methylaminoacetic acidMethylaminoacetic acid(Methylamino)acetic acidSarcosin
16 more reported names
(Methylamino)ethanoic acidAcetic acid, (methylamino)-(methylamino)acetateCHEBI:15611Methylaminoethanoic acidZ711V88R5FN MethylglycineSarcosylate, MagnesiumMETHYL GLYCOCOLLRefChem:181358203-538-62-(methylazaniumyl)acetateSargosine hydrochlorideN-Methyl glycineN-MethylglycocollN-methyl-Glycine
External database identifiers

Evidence from additional scientific databases

EMBL-EBI ChEBI
Exact identifier matchCHEBI:15611

sarcosine

A N-alkylglycine that is the N-methyl derivative of glycine. It is an intermediate in the metabolic pathway of glycine.

Formula
C3H7NO2
Average mass
89.094 g/mol
Monoisotopic mass
89.04768 Da
Formal charge
0
  • N-methylglycines — is a (CHEBI:21766)
  • N-alkylglycine — is a (CHEBI:66933)
  • N-methyl-amino acid — is a (CHEBI:21760)
  • Escherichia coli metabolite — has role (CHEBI:76971)
  • antipsychotic agent — has role (CHEBI:35476)
  • antidepressant — has role (CHEBI:35469)
  • human metabolite — has role (CHEBI:77746)
  • glycine transporter 1 inhibitor — has role (CHEBI:64588)
  • glycine receptor agonist — has role (CHEBI:64589)
  • mouse metabolite — has role (CHEBI:75771)
  • Escherichia coli metabolite — has role (CHEBI:76971)
  • antipsychotic agent — has role (CHEBI:35476)
  • antidepressant — has role (CHEBI:35469)
  • human metabolite — has role (CHEBI:77746)
  • glycine transporter 1 inhibitor — has role (CHEBI:64588)
  • glycine receptor agonist — has role (CHEBI:64589)
  • mouse metabolite — has role (CHEBI:75771)
  • N-methylglycines — is a (CHEBI:21766)
  • N-alkylglycine — is a (CHEBI:66933)
  • N-methyl-amino acid — is a (CHEBI:21760)
  • sarcosinate — is conjugate acid of (CHEBI:46915)
  • sarcosinium — is conjugate base of (CHEBI:46842)
  • sarcosine zwitterion — is tautomer of (CHEBI:57433)
Additional curated names
sarcosineN-methylaminoacetic acidL-sarcosineMeGly(methylamino)acetic acidmethylaminoacetic acidMethylamino-acetic acid(methylamino)ethanoic acidN-MethylglycineSarSarcosineSARCOSINEsarcosinic acid
Cross-references from this source
  • CAS: 107-97-1 — KEGG COMPOUND
  • CAS: 107-97-1 — ChemIDplus
  • CAS: 107-97-1 — NIST Chemistry WebBook
  • REGISTRY_NUMBER: 1699442 — Reaxys
  • REGISTRY_NUMBER: 2018 — Gmelin
  • MANUAL_X_REF: C00213 — KEGG COMPOUND
  • MANUAL_X_REF: c0135 — UM-BBD
  • MANUAL_X_REF: HMDB0000271 — HMDB
  • MANUAL_X_REF: SAR — PDBeChem
  • MANUAL_X_REF: Sarcosine — Wikipedia
  • MANUAL_X_REF: SARCOSINE — MetaCyc

Mapped by: Exact CAS cross-reference in the ChEBI compound record. Source updated: 2016-01-27. Retrieved: 2026-08-31. Open source record

NIH PubChem PUG-View
Exact identifier match1088

Attributed physical-property, hazard, environmental and use annotations.

  • First Aid: EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.; SKIN: IMMEDIATELY flood affected skin with water while removing and isolating all contaminated clothing. Gently wash all affected skin areas thoroughly with soap and water. If symptoms such as redness or irritation develop, IMMEDIATELY call a physician and be prepared to transport the victim to a hospital for treatment.; INHALATION: IMMEDIATELY leave the contaminated area; take deep breaths of fresh air. If symptoms (such as wheezing, coughing, shortness of breath, or burning in the mouth, throat, or chest) develop, call a physician and be prepared to transport the victim to a hospital. Provide proper respiratory protection to rescuers entering an unknown atmosphere. Whenever possible, Self-Contained Breathing Apparatus (SCBA) shou Source: CAMEO Chemicals
  • Note: This chemical does not meet GHS hazard criteria for 98.7% (149 of 151) of all reports. Source: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: Not Classified; Reported as not meeting GHS hazard criteria by 149 of 151 companies (only 1.3% companies provided GHS information). For more detailed information, please visit ECHA C&L website. Source: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: Aggregated GHS information provided per 151 reports by companies from 3 notifications to the ECHA C&L Inventory.; Reported as not meeting GHS hazard criteria per 149 of 151 reports by companies.; There is 1 notification provided by 2 of 151 reports by companies with hazard statement code(s).; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. Source: European Chemicals Agency (ECHA)
  • Health Effects: Acyl sarcosines may cause irritation to the skin and eyes. They may also react to produce N-nitrososarcosine, which is believed to be carcinogenic. (A2881) Source: Toxin and Toxin Target Database (T3DB)
  • Health Effects: Acute Exposure: Can lead to eye and skin irritation. Chronic Exposure: High levels of sarcosine in prostate tissues are associated with aggressive prostate tumors. In this regard, sarcosine appears to function as an oncometabolite. High levels of sarcosine are also seen in patients with sarcosinemia. Sarcosinemia is a rare inborn error of metabolism that is characterized by an increased level of sarcosine (N-methylglycine) in the plasma and urine. The enzymatic block results from a deficiency of sarcosine dehydrogenase (SarDH), a liver mitochondrial matrix enzyme that converts sarcosine into glycine. The disease is mostly characterized by mental delay, cardiomyopathy, deafness and visual disturbance. Source: Toxin and Toxin Target Database (T3DB)
  • Cosmetic Ingredient Review Conclusion: The CIR Expert Panel concluded that the following ingredients are safe as used in cosmetics when formulated to be non-irritating. The Expert Panel cautions that these ingredients should not be used in cosmetic products in which N-nitroso compounds can be found...Cocoyl Sarcosine... Source: Cosmetic Ingredient Review (CIR)
  • Cosmetic Ingredient Review Finding(s): Safe for use in cosmetics, with qualifications Source: Cosmetic Ingredient Review (CIR)
  • Toxicity Summary: While acyl sarcosines themselves are not toxic, they are nitrosating agents. Nitrosating agents may decompose and/or react to cause nitrosamine contamination. Nitrosamines are produced from secondary amines and amides in the presence of nitrite ions and are believed to be carcinogenic. The particular nitrosamine produced by acyl sarcosines is N-nitrososarcosine. Once in the body, nitrosamines are activated by cytochrome P-450 enzymes. They are then believed to induce their carcinogenic effects by forming DNA adducts at the N- and O-atoms. (L1889, L1890, A2878, A2879, A2880, A2881) Source: Toxin and Toxin Target Database (T3DB)
  • Toxicity Summary: Sarcosine is an oncometabolite. Sarcosine appears to upregulate the expression of the potent oncoprotein called human epidermal growth factor receptor 2 (HER2/neu) in androgen-dependent prostate cancer cells upon exposure to exogenous sarcosine. Thus, sarcosine may induce prostate cancer progression by increased HER2/neu expression. Source: Toxin and Toxin Target Database (T3DB)
  • Cosmetic Ingredient Review Link: CIR ingredient: Cocoyl Sarcosine Source: Cosmetic Ingredient Review (CIR)
  • Sources/Uses: Used as an intermediate in synthesis of toothpaste antienzyme agents; [Merck Index] An amino acid intermediate in the metabolism of choline. [ChemIDplus] Used to make antienzyme agents for cosmetics and pharmaceuticals; [NTP] Source: Haz-Map, Information on Hazardous Chemicals and Occupational Diseases
  • Uses: Acyl sarcosines are used as hair-conditioning agents and surfactant-cleansing agents in cosmetics, as well as to improve wetting and penetration of topical pharmaceutical products. Acyl sarcosines and their sodium salts are also used in the metal finishing and processing industries for their crystal modifying, anti-rust, and anti-corrosion properties. (A2881) Source: Toxin and Toxin Target Database (T3DB)
  • Uses: Sarcosine can be used as a cognitive enhancer and to treat schizophrenia. Source: Toxin and Toxin Target Database (T3DB)

Mapped by: Existing checksum-valid CAS to unique PubChem CID match. Retrieved: 2026-08-31. Open source record

Scientific classifications and hazard annotations provide context and do not replace the market-specific regulatory decision shown above.

Additional source coverage and match status
SourceResultChecked
EMBL-EBI ChEBIExact match2026-08-31
NIH PubChem PUG-ViewExact match2026-08-31

A recorded no-match is useful evidence that the source was checked; it is not a claim that the substance does not exist elsewhere.

Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

Additional authoritative substance research

These source-specific lookups can add hazard, toxicology, identity and assessment context. A link is a research route, not a claim that the source contains an exact record.

Cosmetic Ingredient Review safety assessments

Expert Panel conclusions, assessed ingredient groups, use conditions, dates and report documents

Independent expert review considered by FDA; not a government approval or binding market rule

Research this identity

FDA Global Substance Registration System

UNII identifiers, preferred names, substance types, codes and public substance relationships

Identity registry only; UNII availability does not imply FDA review or approval

Research this identity

ILO/WHO International Chemical Safety Cards

Hazards, symptoms, first aid, storage, incompatibilities and physical properties for covered chemicals

International occupational chemical-safety reference; not cosmetic-use approval

Research this identity

Japan NITE-CHRIP

Chemical identity, Japanese and foreign legal lists, GHS hazards and exposure-related information

Chemical-management evidence; cosmetic status remains governed by the applicable MHLW standard and market rules

Research this identity

NIOSH Pocket Guide to Chemical Hazards

REL, PEL, IDLH, properties, exposure routes, symptoms, target organs, first aid and measurement methods for covered workplace chemicals

US occupational-health guidance and limits; not a cosmetic ingredient decision

Research this identity

OECD eChemPortal

Gateway to authority-owned physical-property, fate, ecotoxicity, toxicity, exposure and GHS records

Discovery gateway; each linked authority remains responsible for its data

Research this identity

US EPA CompTox CTX APIs

DTXSID identity, experimental and predicted properties, toxicity, bioactivity, exposure and environmental data

Scientific and computational evidence; predictions must remain labelled and do not determine cosmetic legality

Research this identity

Continue the compliance check

1. Confirm identity

Match the supplier specification, CAS/EC identifiers and composition to this official label name. Similar wording is not proof of chemical equivalence.

2. Review restrictions

Check every exact Annex record shown above, plus CMR, nanomaterial, SCCS and later-amendment requirements that may apply.

3. Verify the formula

Evaluate concentration, product type, purity, warnings, claims and each target market before making a compliance decision.

Screen in a formulaOpen standalone comparison

Official source and scope

Imported from Commission Implementing Decision (EU) 2025/1175 (dataset version EU 2025/1175). The glossary supplies common ingredient names for the ingredient list required by Article 19(1)(g); it is not an approval or safety list.

Open official Decision